You searched for mscs - Page 13 of 19

Clinic versus clinic? Internecine conflicts among direct-to-consumer stem cell firms

February 6, 2018 February 1, 2021 / By Professor Paul Knoepfler, Ph.D. / 8 Comments

Stem cell clinics marketing non-FDA approved therapies directly to consumers have been in various tense situations at times with the FDA or academics over the years, but more recently these stem cell clinic-related firms also appear in conflict with each other sometimes. The most notable recent example of conflict involves Dr. Christopher Centeno of Regenexx …

Clinic versus clinic? Internecine conflicts among direct-to-consumer stem cell firms Read More »

Stem cell therapy review of good news: UC Davis, Asterias, Cynata, Mesoblast, ViaCyte

August 27, 2017 February 1, 2021 / By Professor Paul Knoepfler, Ph.D. / 2 Comments

VC-01-post-implant-final1-e1503703572933, viacyte

It’s a difficult, but very important road to conclusively prove that an investigational stem cell therapy is both safe and effective in order to get final approval FDA or equivalents in other countries. For this reason, it is beneficial to highlight even small, but positive steps forward including encouraging pre-clinical data. Today I’m doing a …

Stem cell therapy review of good news: UC Davis, Asterias, Cynata, Mesoblast, ViaCyte Read More »

Cynata stem cell trial update: CEO Ross Macdonald interview

July 3, 2017 February 22, 2021 / By Professor Paul Knoepfler, Ph.D. / 2 Comments

Koch-et-al_2016_MCA-derived-MSC-Treatment-of-Hindlimb-Ischemia-in-Mice-e1498668676851

Stem cell clinical trials have a certain gravitational pull for me as I’m always fascinated by them and since the new Cynata trial is moving forward, I recently did an interview their CEO, Dr. Ross A. Macdonald to find out more. PK: Cynata’s recently initiated clinical trial aims to treat GVHD as have other stem …

Cynata stem cell trial update: CEO Ross Macdonald interview Read More »

Hunting for computational approaches for stem cells at ISSCR2017

June 20, 2017 February 1, 2021 / By Professor Paul Knoepfler, Ph.D. / 7 Comments

By Cátia Bandeiras, PhD Student at University of Lisbon, Portugal and Massachusetts Institute of Technology. See tweets from the conference using #ISSCR2017 @apulgarita I just wrapped up my stay at the Annual Meeting of ISSCR 2017, which happened in Boston. I decided to take advantage of the fact that I am living in Boston at …

Hunting for computational approaches for stem cells at ISSCR2017 Read More »

20 Nominees for Stem Cell Person of the Year 2016 Award

December 4, 2016 December 22, 2023 / By Professor Paul Knoepfler, Ph.D. / 4 Comments

I received a score of great nominations for the Stem Cell Person of the Year 2016 Award and have briefly described the twenty nominees below. The point of the award is to honor the top positive stem cell leader who specifically thinks outside the box and takes risks. I’ve started an on-line vote where you can vote once per day for …

20 Nominees for Stem Cell Person of the Year 2016 Award Read More »

Where does stem cell business Stemedica go from here after KPBS investigative report?

October 5, 2016 February 1, 2021 / By Professor Paul Knoepfler, Ph.D. / 9 Comments

For quite a while there San Diego-based stem cell business Stemedica had a good run of publicity with reports of high-profile professional sports legends getting stem cells and the media reporting apparent good outcomes for stroke recovery, but more recent times have yielded some different publicity. An investigative report by KPBS reporter David Wagner raised some …

Where does stem cell business Stemedica go from here after KPBS investigative report? Read More »

8 key arguments, take-homes on day 1 of FDA stem cell meeting

September 12, 2016 February 1, 2021 / By Professor Paul Knoepfler, Ph.D. / 4 Comments

Today was the first part of the FDA’s 2-day meeting on stem cell draft guidances. It was a great meeting I thought. A few consistent themes and notable things emerged as raised by participants.

Negative stem cell clinic outcomes include 3 blinded women

September 8, 2016 February 1, 2021 / By Professor Paul Knoepfler, Ph.D. / 6 Comments

What can go wrong with unapproved stem cell clinic offerings? The answer including from presentations at the FDA today turns out to be very serious, negative results right here in the U.S. Thomas Albini, MD gave a talk entitled, “Severe Visual Loss After Intravitreal Injection of Autologous Adipose Tissue-derived Stem Cells for Age-related Macular Degeneration”. …

Negative stem cell clinic outcomes include 3 blinded women Read More »

UC Davis CRISPR Meeting Panel: A View from the Trenches on Human Disease

May 26, 2016 February 1, 2021 / By Professor Paul Knoepfler, Ph.D. / 3 Comments

The second session at our CRISPR meeting was really powerful. As with other posts from the UC Davis CRISPR meeting, since I was taking notes on the fly during this session, this post is a stream of bits from the different talks, often trying to capture the essence of key questions or ideas as the speakers …

UC Davis CRISPR Meeting Panel: A View from the Trenches on Human Disease Read More »

Review of Centeno MSC safety paper: without controls, conclusions muted

April 11, 2016 February 1, 2021 / By Professor Paul Knoepfler, Ph.D. / 22 Comments

The number of people around the world being injected with stem cells every day has never been higher and the heterogeneous group of medical providers doing these procedures is also at or near its highest level ever. The cells used are also highly variable as are the procedures themselves, but most of these cells fall under the …

Review of Centeno MSC safety paper: without controls, conclusions muted Read More »

Search Results for: mscs